

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2020202573 B2**

(54) Title
Use of long-acting GLP-1 peptides

(51) International Patent Classification(s)
A61K 38/26 (2006.01) **A61P 3/10** (2006.01)
A61P 3/04 (2006.01) **A61P 5/50** (2006.01)

(21) Application No: **2020202573** (22) Date of Filing: **2020.04.16**

(43) Publication Date: **2020.05.07**

(43) Publication Journal Date: **2020.05.07**

(44) Accepted Journal Date: **2023.04.20**

(62) Divisional of:
2018202504

(71) Applicant(s)
Novo Nordisk A/S

(72) Inventor(s)
Jensen, Christine Bjorn;Rasmussen, Mads Frederik;Zdravkovic, Milan;Kristensen, Peter

(74) Agent / Attorney
Pearce IP Pty Ltd, L5, 20 Bond St, SYDNEY, NSW, 2000, AU

(56) Related Art
WO 2010/092163 A2
Clinical Trial NCT00696657, entitled "A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide," pp. 1-5 (3/11/2015), URL clinicaltrials.gov/archive/NCT00696657/2011_03_25